Dual FXR/GPBAR1 agonist (INT-767) significantly inhibits the development of liver inflammation and fibrosis in NAFLD mice, and the mechanism is that INT-767 promotes the increase of Ly6Clow monocytes and decrease of Ly6Chigh monocytes by directly targeting Ly6C levels. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.